SCHEMBL4298741

SCHEMBL4298741

CCCCCCCCCCc1ccc(CCNC2CC(C(=O)O)(C(=O)OCC)C2)c(F)c1F

nearest known ligand 0.35

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 10/20 0.35
CNR1 P21554 6/20 0.35
KDM4E B2RXH2 2/20 0.33
NOD2 Q9HC29 1/20 0.33
TSHR P16473 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5796212 0.99 CNR2 (0.35) CNR2CNR1KDM4ENOD2TSHR
SCHEMBL4287098 0.92 CNR2 (0.35) CNR2CNR1KDM4ETSHR
SCHEMBL4293681 0.90 CNR2 (0.37) CNR2CNR1TSHR
SCHEMBL4288412 0.90 CNR2 (0.36) CNR2CNR1KDM4E
SCHEMBL4288421 0.90 CNR2 (0.36) CNR2CNR1KDM4E
SCHEMBL5795055 0.87 SPHK1 (0.37)
SCHEMBL4287290 0.87 CNR2 (0.38) CNR2CNR1KDM4E
SCHEMBL4287270 0.87 CNR2 (0.38) CNR2CNR1KDM4E
SCHEMBL5797229 0.86 CNR2 (0.34) CNR2CNR1KDM4E
SCHEMBL4286878 0.85 SPHK1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES BIO-PROJET (FR) 2009-10-22 US claimed
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES BIO-PROJET (FR) 2009-10-22 US disclosed
WO-2006043149-A9 NOVEL DICARBOXYLIC ACID DERIVATIVES BIOPROJET SOC CIV (FR) 2006-08-10 WO disclosed
WO-2006043149-A2 NOVEL DICARBOXYLIC ACID DERIVATIVES BIOPROJET (FR) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES S1PR2, S1PR1, S1PR5 CNR2 25/4885CNR1 27/4885KDM4E 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.